{"organizations": [], "uuid": "1d17eecb532b0df3978fe7cac743a19afe1a5803", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180215.html", "section_title": "Archive News &amp; Video for Thursday, 15 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/merck-lungcancer/merck-kgaa-pfizers-immunotherapy-fails-in-lung-cancer-trial-idUSF9N0NT023", "country": "US", "domain_rank": 408, "title": "Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.003, "site_type": "news", "published": "2018-02-15T21:34:00.000+02:00", "replies_count": 0, "uuid": "1d17eecb532b0df3978fe7cac743a19afe1a5803"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/merck-lungcancer/merck-kgaa-pfizers-immunotherapy-fails-in-lung-cancer-trial-idUSF9N0NT023", "ord_in_thread": 0, "title": "Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial", "locations": [], "entities": {"persons": [{"name": "bavencio", "sentiment": "negative"}, {"name": "edward taylor", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}], "locations": [{"name": "frankfurt", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "merck kgaa", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "negative"}, {"name": "ludwig burger", "sentiment": "none"}, {"name": "merck", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "FRANKFURT, Feb 15 (Reuters) - Merck KGaA and Pfizerâ€™s cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.\nThe results revealed on Thursday mark another setback for a drug that is a late starter in the rapidly evolving field of cancer immunotherapies.\nMerck shares turned negative following the news, trading 1.1 percent lower. (Reporting by Ludwig Burger; Editing by Edward Taylor)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-15T21:34:00.000+02:00", "crawled": "2018-02-16T17:02:12.002+02:00", "highlightTitle": ""}